3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells

Estimated Cause-specific Survival Continues to Improve Over Time in Patients With Chondrosarcoma

(2014) Kyle R. Duchman et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

3-Deazaneplanocin A (DZNep), an Inhibitor ofS-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation

(2014) Tohru Fujiwara et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Advanced chondrosarcomas: role of chemotherapy and survival

(2013) A. Italiano et al.   ANNALS OF ONCOLOGY

Polycomb complexes in stem cells and embryonic development

(2013) L. Aloia et al.   DEVELOPMENT

Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell Lines

(2013) Ramez N. Eskander et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity

(2013) X Zhao et al.   LEUKEMIA

Pharmacological Reversal of Histone Methylation Presensitizes Pancreatic Cancer Cells to Nucleoside Drugs: In Vitro Optimization and Novel Nanoparticle Delivery Studies

(2013) Sau Wai Hung et al.   PLoS One

The Polycomb Protein Ezh2 Impacts on Induced Pluripotent Stem Cell Generation

(2013) Xiaolei Ding et al.   STEM CELLS AND DEVELOPMENT

Cell Reprogramming Requires Silencing of a Core Subset of Polycomb Targets

(2013) Giulia Fragola et al.   PLoS Genetics

EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis

(2012) Francesco Crea et al.   CANCER AND METASTASIS REVIEWS

TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)

(2012) L. L. Cheng et al.   CLINICAL CANCER RESEARCH

EZH2 couples pancreatic regeneration to neoplastic progression

(2012) J. Mallen-St. Clair et al.   GENES & DEVELOPMENT

Clinical outcome of central conventional chondrosarcoma

(2012) Andrea Angelini et al.   JOURNAL OF SURGICAL ONCOLOGY

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

(2012) Karolina Holm et al.   Molecular Oncology

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

New lysine methyltransferase drug targets in cancer

(2012) Tobias Wagner et al.   NATURE BIOTECHNOLOGY

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

(2012) W. Qi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

(2011) J. Zhou et al.   BLOOD

(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells

(2011) S. R. Choudhury et al.   CARCINOGENESIS

Aberrations of EZH2 in Cancer

(2011) A. Chase et al.   CLINICAL CANCER RESEARCH

Polycomb genes and cancer: Time for clinical application?

(2011) Francesco Crea et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells

(2011) A. H. Juan et al.   GENES & DEVELOPMENT

3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells

(2011) Tetsuhiro Chiba et al.   INTERNATIONAL JOURNAL OF CANCER

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

(2011) Francesco Crea et al.   Molecular Cancer

Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer

(2011) H Taniguchi et al.   ONCOGENE

Histone lysine methylation and demethylation pathways in cancer

(2010) Radhika A. Varier et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition

(2010) Annette Hayden et al.   BREAST CANCER RESEARCH AND TREATMENT

RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo

(2010) Yangchao Chen et al.   CANCER LETTERS

ESCs Require PRC2 to Direct the Successful Reprogramming of Differentiated Cells toward Pluripotency

(2010) Carlos F. Pereira et al.   Cell Stem Cell

Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells

(2010) H. Li et al.   MOLECULAR CANCER RESEARCH

Epigenetic modifications as therapeutic targets

(2010) Theresa K Kelly et al.   NATURE BIOTECHNOLOGY

An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB

(2010) Junxia Min et al.   NATURE MEDICINE

The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer

(2010) J Yu et al.   ONCOGENE

Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis

(2010) L. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance

(2009) M.-L. Suva et al.   CANCER RESEARCH

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

(2009) T. B. Miranda et al.   MOLECULAR CANCER THERAPEUTICS

Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2

(2008) A. V. Ougolkov et al.   CLINICAL CANCER RESEARCH

Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation

(2008) Satoshi Fujii et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

(2008) Q Cao et al.   ONCOGENE